Craniopharyngioma
Therapeutic area
Neurology
Rare disease
Yes
- Definition
- A benign, partly cystic, epithelial tumor of the sellar region, presumably derived from Rathke pouch epithelium. It affects mainly children and young adults. There are two clinicopathological forms: adamantinomatous craniopharyngioma and papillary craniopharyngioma. The most significant factor associated with recurrence is the extent of surgical resection, with lesions greater than 5 cm in diameter carrying a markedly worse prognosis. (Adapted from WHO)
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Craniopharyngioma
- Therapeutic area
- Neurology
- craniopharyngioma
- Rathke pouch neoplasm
- Rathke pouch tumor
- Rathke pouch tumour
- Rathke's pouch neoplasm
- Rathke's pouch tumor
- Rathke's pouch tumour
- craniopharyngioma (WHO grade I)
- craniopharyngioma (morphologic abnormality)
- craniopharyngioma, benign
- neoplasm of Rathke's pouch
- tumor of Rathke's pouch
- tumour of Rathke's pouch
- Adamantinomatous tumor
- Adamantinomatous tumour
- Dysodontogenic epithelial tumor
- Dysodontogenic epithelial tumour
- craniopharyngeal duct tumor
- craniopharyngeal duct tumour
- Severity
- Mild
- Neurology
- Oncology
- Rheumatology
- MONDO ID
- MONDO:0018907
- Parent condition
- MONDO:0000628
Related records
Broader conditions (33)
- Benign connective and soft tissue neoplasm
- Benign epithelial neoplasm
- Benign neoplasm
- Bone benign neoplasm
- Bone disorder
- Bone neoplasm
- Cancer or benign tumor
- Central nervous system disorder
- Central nervous system neoplasm
- Central nervous system organ benign neoplasm
- Connective and soft tissue neoplasm
- Connective tissue disorder
- Connective tissue neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disorder of facial skeleton
- Epithelial neoplasm
- Head and neck neoplasm
- Human disease
Narrower conditions (2)
- Adamantinous craniopharyngioma
- Papillary craniopharyngioma
Trials (71)
- 1.5T Intraoperative MR Imaging in Craniopharyngiomas
- A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
- A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
- A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection
- ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
- Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
- AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors
- An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury
- Antineoplaston Therapy in Treating Children With Brain Tumors
- Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
- Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
- Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
- Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors
- Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery
- Craniopharyngioma and Pregnancies
- Craniopharyngioma With Tumoral Hemorrhage
- Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial
- Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
- Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions
- Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions
Drugs in development (9)
- Cobimetinib Phase 2
- Dabrafenib Phase 2
- Dextrose Phase 2
- Methionine Phase 2
- Nivolumab Phase 2
- Peginterferon alfa-2B Phase 2
- Tovorafenib Phase 2
- Trametinib Phase 2
- Vemurafenib Phase 2